Abstract: A device, system, and method tracks a job management. The method performed by a central processing server includes receiving a layout drawing of an installation job, the layout drawing including a plurality of components to be installed at a work site. The method includes receiving status information of the components as a status of the components is updated. The method includes dynamically updating a current status for each of the components upon receiving the status information. The method includes receiving a request for a status update from a user device for a selected component of the components. The method includes determining the current status of the selected component. The method includes transmitting, by the server, the current status of the selected component to the user device.

Abstract: Provided herein are methods for the modulation of appearance or material properties within items of apparel or equipment. Also provided herein are design articles having alterable designs.

Abstract: The present invention relates to the uses of the protein PRG4 and therapeutic modulation thereof. In particular, the present invention relates compositions and methods utilizing PRG4 and therapeutic modulation thereof, including, use as a surgical lubricant, use in a treatment for prevention or reduction of post-surgical adhesions, use in a treatment for oral ulcerations, use as an athletic lubricating patch, use as a dermal filler, use in a treatment for dry mouth, use in a drug delivery method or composition, and use in nursing lubrication.

Abstract: The present invention provides a pharmaceutical composition, and methods of use thereof, for treating ocular boundary deficiency, symptoms associated therewith, or an undesired condition that is associated with or causes ocular boundary deficiency at the ocular surface. The pharmaceutical composition of the present invention comprises a human PRG4 protein, a lubricant fragment, homolog, or isoform thereof, suspended in an ophthalmically acceptable balanced salt solution. The pharmaceutical composition of the present invention may also comprise one or more ophthalmically acceptable agents selected from the group consisting of an ophthalmically acceptable demulcent, excipient, astringent, vasoconstrictor, emollient, sodium hyaluronate, hyaluronic acid, and surface active phospholipids, in a pharmaceutically acceptable carrier for topical administration.

Abstract: Various embodiments include a method of displacing a turbomachine component from position in a first slot of a turbomachine spacer disk. The method can include detachably affixing a mounting member of a displacement apparatus to a second slot in the gas turbomachine spacer disk using an attachment device, rotating a displacement arm of the displacement apparatus until the displacement arm contacts the turbomachine component, and displacing the turbomachine component from the position within the first slot by linearly actuating the displacement arm with a linear actuator.

Abstract: A tool for installing a turbomachine component in a first dovetail slot of a first component mount is provided. The tool may include a tool mount having a body for selective fixing in a second dovetail slot of a second component mount adjacent to the first component mount. The tool may also include a lever arm including a first portion, an intermediate pivot for pivotally engaging the tool mount, and a second portion for engaging the turbine component. Actuating the lever arm against the tool mount causes the second portion of the lever arm to install the turbomachine component into the first dovetail slot of the first component.

Abstract: A tool for removing a component from a turbomachine is provided. The tool includes a body having an alignment portion and a connection portion. The alignment portion defines a longitudinal axis and a cross sectional shape complementary to a slot defined in a rotor wheel of the turbomachine. When the tool is positioned in the slot, the connection portion is configured to contact the component. The tool additionally includes a force section connected to the body and configured to transfer a force to the connection portion in a direction substantially parallel to the longitudinal axis of the alignment portion.

Abstract: Provided herein are methods for the modulation of appearance or material properties within items of apparel or equipment. Also provided herein are design articles having alterable designs.

Abstract: Various embodiments include methods adapted to displace turbomachine components from a location within a turbomachine. In some embodiments, a method of displacing a turbine bucket from a turbomachine wheel slot using a displacement apparatus, includes: detachably engaging an engagement arm of the displacement apparatus to the turbine bucket, the engagement arm attached to a linear actuator coupled to a body of the displacement apparatus, and the engagement arm adapted to be actuated in a first axial direction by the linear actuator; contacting the turbomachine wheel with at least two contacting portions of the body of the displacement apparatus; and displacing the turbine bucket from a position within a slot of the turbomachine wheel in the first axial direction by linearly actuating the engagement arm with the linear actuator.

Abstract: The present invention provides a pharmaceutical composition, and methods of use thereof, for treating ocular boundary deficiency, symptoms associated therewith, or an undesired condition that is associated with or causes discomfort at the ocular surface. The pharmaceutical composition of the present invention comprises a human PRG4 protein, or a lubricating fragment thereof, suspended in an ophthalmically acceptable vehicle. The pharmaceutical composition of the present invention may also comprise one or more ophthalmically acceptable agents selected from the group consisting of an ophthalmically acceptable demulcent, excipient, astringent, vasoconstrictor, emollient, sodium hyaluronate, hyaluronic acid, and surface active phospholipids, in a pharmaceutically acceptable carrier for topical administration.

Abstract: Provided herein are methods for the modulation of appearance or material properties within items of apparel or equipment. Also provided herein are design articles having alterable designs. Generally, such design articles comprise (1) a microfluidic circuit, and (2) an inlet and an outlet, the alterable design capable of being modulated through use of a docking system to deliver fluid to the microfluidic circuit.

Abstract: Various embodiments include a method of displacing a turbomachine component from position in a first slot of a turbomachine spacer disk. The method can include detachably affixing a mounting member of a displacement apparatus to a second slot in the gas turbomachine spacer disk using an attachment device, rotating a displacement arm of the displacement apparatus until the displacement arm contacts the turbomachine component, and displacing the turbomachine component from the position within the first slot by linearly actuating the displacement arm with a linear actuator.

Abstract: Various embodiments include methods adapted to displace turbomachine components from a location within a turbomachine. In some embodiments, a method of displacing a turbine bucket from a turbomachine wheel slot using a displacement apparatus, includes: detachably engaging an engagement arm of the displacement apparatus to the turbine bucket, the engagement arm attached to a linear actuator coupled to a body of the displacement apparatus, and the engagement arm adapted to be actuated in a first axial direction by the linear actuator; contacting the turbomachine wheel with at least two contacting portions of the body of the displacement apparatus; and displacing the turbine bucket from a position within a slot of the turbomachine wheel in the first axial direction by linearly actuating the engagement arm with the linear actuator.

Abstract: A method for forming a catalyst can comprise: heating a Ge-ZSM-5 zeolite powder at a temperature of 400 to 600° C.; ion-exchanging the heat-treated zeolite powder with an alkali metal and impregnating the heat-treated zeolite powder with noble metal; heating the ion-exchanged, impregnated zeolite powder to a temperature of 250 to 350° C.; mixing the second heat-treated zeolite powder with a solid silica binder and a colloidal silica binder to form a mixture, wherein if the solid silica has a purity of less than or equal to 66 wt % of silica oxide based on the total weight of the solid silica, then the mixture is free of an extrusion aide and the colloidal silica has a particle size of less than 20 nm as measured along a major axis; forming the mixture into a shaped body; and heating the shaped body to 100 to 350° C. to result in the catalyst.

Abstract: Various embodiments include apparatuses adapted to displace components from a location within a turbomachine. In some embodiments an apparatus for displacing a component of a gas turbine from a first slot in a spacer disk includes a body including a mounting member configured to affixedly attach to a second slot of the spacer disk, a linear actuator coupled to the body and a displacement arm coupled to the linear actuator, the displacement arm actuatable in a first axial direction by the linear actuator to contact the component and displace the component relative to the first slot.

Abstract: Provided herein are ophthalmically acceptable pharmaceutical compositions comprising PRG4 or lubricant fragments and a PRG4 inducing compound. The PRG4 inducing compound in the pharmaceutical composition of the present invention upregulates PRG4 expression and localization in the ocular surface for efficient surface boundary lubrication. In some instances, pharmaceutical compositions described herein are utilized for treating ophthalmic conditions, e.g., ocular boundary deficiency and symptoms associated therewith.

Abstract: The present invention provides a pharmaceutical composition, and methods of use thereof, for treating ocular boundary deficiency, symptoms associated therewith, or an undesired condition that is associated with or causes ocular boundary deficiency at the ocular surface. The pharmaceutical composition of the present invention comprises a human PRG4 protein, a lubricant fragment, homolog, or isoform thereof, suspended in an ophthalmically acceptable balanced salt solution. The pharmaceutical composition of the present invention may also comprise one or more ophthalmically acceptable agents selected from the group consisting of an ophthalmically acceptable demulcent, excipient, astringent, vasoconstrictor, emollient, sodium hyaluronate, hyaluronic acid, and surface active phospholipids, in a pharmaceutically acceptable carrier for topical administration.

Abstract: The present invention provides a pharmaceutical composition, and methods of use thereof, for treating ocular boundary deficiency, symptoms associated therewith, or undesired condition that is associated with or causes ocular boundary deficiency at the ocular surface. The pharmaceutical composition of the present invention comprises a human PRG4 protein, a lubricant fragment, homolog, or isoform thereof, suspended in an ophthalmically acceptable balanced salt solution. The pharmaceutical composition of the present invention may also comprise one or more ophthalmically acceptable agents selected from the group consisting of an ophthalmically acceptable demulcent, excipient, astringent, vasoconstrictor, emollient, sodium hyaluronate, hyaluronic acid, and surface active phospholipids, in a pharmaceutically acceptable carrier for topical administration.

Abstract: Various embodiments include apparatuses adapted to displace turbomachine components from a location within a turbomachine. In some embodiments apparatuses for displacing a turbine bucket from a turbomachine wheel slot include a body having at least two contacting portions for contacting the turbomachine wheel, a linear actuator coupled to the body, and an engagement arm for engaging the turbine bucket, the engagement arm coupled to the linear actuator and adapted to be actuated in a first axial direction by the linear actuator.

Abstract: Embodiments of the present disclosure include apparatuses and systems used for the positioning of equipment. An apparatus according to an embodiment of the present disclosure can include a height adjustable table; a platform coupled to the height adjustable table; a tilt adjuster coupled to the platform, the tilt adjuster being configured to tilt the platform relative to the height adjustable table; an equipment support structure slidably connected to the platform, the equipment support structure being configured to support a piece of equipment; a drive mechanism coupled to the platform and configured to slidably move the equipment support structure across the platform; and a bracket coupled to the equipment support structure, wherein the bracket is configured to removably attach the piece of equipment.